Prospective, Multicentre, Open-Label Study Evaluating 1,5 mg/Day of Fondaparinux. - Related Studies

Prospective, Multicentre, Open-Label Study Evaluating 1,5 mg/Day of Fondaparinux. (PROPICE)

This study has been completed.

Study NCT00555438. Last updated on October 13, 2008. Information provided by Centre Hospitalier Universitaire de Saint Etienne

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Interventions listed in this trial
		fondaparinux 1,5 mg/day

2	Additional drug interventions recognized in this trial
		Fondaparinux
		Org 31540

3	More general drug interventions related to this trial
		Anticoagulants
		Cardiovascular Agents
		Fibrin Modulating Agents
		Fibrinolytic Agents
		Hematologic Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses

4	Sponsors listed in this trial
		Centre Hospitalier Universitaire de Saint Etienne
		GlaxoSmithKline